- Home
- XPEL vs GERN Comparison
XPEL vs GERN Comparison
Compare XPEL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPEL
- GERN
- Stock Information
- Founded
- XPEL 1999
- GERN 1990
- Country
- XPEL United States
- GERN United States
- Employees
- XPEL N/A
- GERN N/A
- Industry
- XPEL Industrial Specialties
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- XPEL Industrials
- GERN Health Care
- Exchange
- XPEL Nasdaq
- GERN Nasdaq
- Market Cap
- XPEL 984.3M
- GERN 823.0M
- IPO Year
- XPEL N/A
- GERN 1996
- Fundamental
- Price
- XPEL $36.23
- GERN $1.27
- Analyst Decision
- XPEL
- GERN Buy
- Analyst Count
- XPEL 0
- GERN 7
- Target Price
- XPEL N/A
- GERN $3.17
- AVG Volume (30 Days)
- XPEL 253.8K
- GERN 7.6M
- Earning Date
- XPEL 11-05-2025
- GERN 11-06-2025
- Dividend Yield
- XPEL N/A
- GERN N/A
- EPS Growth
- XPEL 2.75
- GERN N/A
- EPS
- XPEL 1.76
- GERN N/A
- Revenue
- XPEL $448,897,000.00
- GERN $164,447,000.00
- Revenue This Year
- XPEL $12.54
- GERN $172.62
- Revenue Next Year
- XPEL $10.52
- GERN $56.87
- P/E Ratio
- XPEL $20.98
- GERN N/A
- Revenue Growth
- XPEL 9.96
- GERN 11877.20
- 52 Week Low
- XPEL $24.25
- GERN $1.09
- 52 Week High
- XPEL $47.23
- GERN $4.50
- Technical
- Relative Strength Index (RSI)
- XPEL 61.98
- GERN 47.04
- Support Level
- XPEL $35.42
- GERN $1.19
- Resistance Level
- XPEL $37.71
- GERN $1.31
- Average True Range (ATR)
- XPEL 0.92
- GERN 0.06
- MACD
- XPEL 0.28
- GERN 0.00
- Stochastic Oscillator
- XPEL 72.35
- GERN 28.85
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.